Skip to main content
CADL
NASDAQ Life Sciences

Candel Therapeutics 与EVERSANA合作，为前列腺癌药物Aglatimagene Besadenovec的潜在美国推广提供支持

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$6.3
Mkt Cap
$454.131M
52W Low
$4.338
52W High
$7.655
Market data snapshot near publication time

summarizeSummary

Candel Therapeutics宣布与EVERSANA签订商业化协议，以支持其主要免疫治疗候选药物Aglatimagene Besadenovec在美国的潜在推广，用于中度至高风险的局部前列腺癌。该正式协议是在公司之前报告的阳性III期前列腺癌数据和RMAT指定，以及早期提到的预商业化工作流之后签订的。EVERSANA将提供广泛的商业化服务，包括数据和分析、医学事务、市场准入和现场运营， 为Candel公司计划在2026年第四季度提交生物制剂许可申请（BLA）做好准备。这一合作伙伴关系是临床阶段生物制药公司的一项重要步骤，显著降低了其主要资产的商业化风险，并使其更接近潜在的收入产生。投资者现在将关注即将到来的BLA提交和随后的监管审查。

在该公告发布时，CADL的交易价格为$6.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$4.5亿。 52周交易区间为$4.34至$7.66。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CADL - Latest Insights

CADL
Apr 29, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Proxy Statement Details Over $200M in Capital Raises with Strong Insider Participation
Sentiment: Neutral
View Wiseek Article
CADL
Apr 29, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Candel Therapeutics Secures EVERSANA Partnership for Potential U.S. Launch of Prostate Cancer Drug Aglatimagene Besadenovec
Sentiment: Positive
View Wiseek Article
CADL
Mar 18, 2026, 4:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Major Insider Group Buys $3.0M in Shares Ahead of Positive Clinical Data Announcements
Sentiment: Positive
View Wiseek Article
CADL
Mar 17, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Candel's CAN-2409 Shows Significant Survival Extension, Two-Fold mOS Improvement in Advanced NSCLC
Sentiment: Positive
View Wiseek Article
CADL
Mar 12, 2026, 8:17 AM EDT
Filing Type: 10-K
Importance Score:
9
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Data, Secures $100M Contingent Royalty Deal, and Extends Runway with $93.5M Offering
Sentiment: Positive
View Wiseek Article
CADL
Mar 12, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Candel Therapeutics Targets Q4 2026 BLA for Prostate Cancer Drug, Initiates Pivotal NSCLC Phase 3, Secures Funding
Sentiment: Positive
View Wiseek Article
CADL
Feb 26, 2026, 7:38 PM EST
Filing Type: 4
Importance Score:
9
Director Paul Manning Buys Nearly $3M in Candel Therapeutics Stock
Sentiment: Positive
View Wiseek Article
CADL
Feb 23, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Candel Therapeutics Formalizes $100M Public Offering, Extends Cash Runway to Q1 2028
Sentiment: Neutral
View Wiseek Article
CADL
Feb 20, 2026, 4:16 PM EST
Filing Type: 424B5
Importance Score:
8
Candel Therapeutics Finalizes $100M Public Offering, Extending Cash Runway for Key Programs
Sentiment: Neutral
View Wiseek Article
CADL
Feb 19, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
Candel Therapeutics Announces $100 Million Common Stock Offering, Extending Cash Runway to Q1 2028
Sentiment: Negative
View Wiseek Article